Actelion patents expiration
1. Opsumit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7094781 | ACTELION | Sulfamides and their use as endothelin receptor antagonists |
Dec, 2025
(1 year, 7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10946015 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
Sep, 2026
(2 years from now) | |
| US9265762 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
May, 2027
(3 years from now) | |
| US8367685 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
Oct, 2028
(4 years from now) | |
| US8268847 | ACTELION | Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor |
Apr, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 18, 2018 |
| Orphan Drug Exclusivity(ODE) | Oct 18, 2020 |
| Orphan Drug Exclusivity(ODE-54) | Oct 18, 2020 |
Drugs and Companies using MACITENTAN ingredient
NCE-1 date: 18 October, 2017
Market Authorisation Date: 18 October, 2013
Treatment: Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherein the polysorbate represents 0.1 to 1% of the weight of ...
Dosage: TABLET;ORAL
OPSUMIT family patents
2. Tracleer patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5292740 | ACTELION | Sulfonamides |
Nov, 2015
(8 years ago) | |
| US8309126 | ACTELION | Dispersible bosentan tablet |
May, 2026
(2 years from now) | |
| US7959945 | ACTELION | Dispersible bosentan tablet |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | Sep 05, 2024 |
| New Patient Population(NPP) | Sep 05, 2020 |
| New Indication(I-607) | Aug 07, 2012 |
Drugs and Companies using BOSENTAN ingredient
Market Authorisation Date: 20 November, 2001
Treatment: NA
Dosage: TABLET;ORAL; TABLET, FOR SUSPENSION;ORAL
TRACLEER family patents
3. Uptravi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7205302 | ACTELION | Heterocyclic compound derivatives and medicines |
Oct, 2026
(2 years from now) | |
| US8791122 | ACTELION | Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same |
Aug, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9173881 | ACTELION | Therapeutic compositions containing macitentan |
Aug, 2029
(5 years from now) | |
| US9284280 | ACTELION | Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Jun, 2030
(6 years from now) | |
| US10828298 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide |
Dec, 2036
(12 years from now) | |
| US10821108 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Dec, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-106) | Dec 21, 2022 |
| Orphan Drug Exclusivity(ODE) | Dec 21, 2022 |
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2020 |
Drugs and Companies using SELEXIPAG ingredient
NCE-1 date: 22 December, 2019
Market Authorisation Date: 21 December, 2015
Treatment: Method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist macitentan; Method of treating pulmonary arterial hypertens...
Dosage: TABLET;ORAL; POWDER;INTRAVENOUS
UPTRAVI family patents
4. Veletri patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8598227 | ACTELION | Epoprostenol formulation and method of making thereof |
Feb, 2027
(2 years from now) | |
| US8318802 | ACTELION | Epoprostenol formulation and method of making thereof |
Mar, 2027
(2 years from now) | |
Drugs and Companies using EPOPROSTENOL SODIUM ingredient
Market Authorisation Date: 28 June, 2012
Treatment: NA
Dosage: INJECTABLE;INJECTION
VELETRI family patents
5. Zavesca patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5472969 | ACTELION | Method of inhibiting glycolipid synthesis |
May, 2013
(10 years ago) | |
| US5525616 | ACTELION | Method of inhibiting glycolipid synthesis |
Jun, 2013
(10 years ago) | |
Drugs and Companies using MIGLUSTAT ingredient
Market Authorisation Date: 31 July, 2003
Treatment: NA
Dosage: CAPSULE;ORAL
ZAVESCA family patents